ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology

Empowering researchers with superior imaging performance for cutting-edge live-cell and three-dimensional applications

Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity for thicker samples such as tissues and 3-D spheroids.

In light microscopy, water immersion technology automatically and consistently places a layer of water between the objective lens and the sample. The higher refractive index of water, as compared to air, effectively increases the numerical aperture of the objective lens; this reduces z-axis distortion, resulting in higher image quality and a more true-to-life representation of thick and three-dimensional cell models. Water immersion also benefits researchers who are increasingly turning to physiologically relevant live-cell (as opposed to fixed-cell) applications by reducing exposure times, thus lowering the phototoxic effects traditionally associated with these experiments.

Spinning disk confocal technology improves microscopic images by blocking out-of-focus light from reaching the image sensor. The new deep-sectioning spinning disk (DSD), now available as an option on the Cytation C10, allows researchers to look deeper into thick samples with less out-of-focus blur. The clearer images that result are particularly beneficial in quantitative analysis applications.

“The additions of water immersion objectives and a deep-sectioning confocal spinning disk to the Cytation C10 add significant new capabilities for researchers requiring the best imaging performance for live-cell and 3D applications,” stated Caleb Foster, associate vice president of marketing in Agilent’s Cell Analysis Division. “As the demands continue to grow for more complex physiologically relevant live-cell models, the Cytation C10 will be an invaluable and transformative research tool to support these imaging application areas.”

Designed as an affordable, high-performance confocal microscopy system, the Cytation C10 employs high-quality components, including a Hamamatsu scientific CMOS (sCMOS) camera, Olympus objectives, and laser-based illumination. Onboard environmental controls, widefield fluorescence, brightfield, and phase contrast optics further enhance the system’s capabilities. Additionally, integrating it with the Agilent BioTek BioSpa 8 automated incubator enables efficient multi-plate live-cell analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.